Compare CAL & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAL | CBIO |
|---|---|---|
| Founded | 1878 | 2003 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Shoe Manufacturing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.1M | 482.6M |
| IPO Year | 1994 | N/A |
| Metric | CAL | CBIO |
|---|---|---|
| Price | $11.74 | $16.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $15.00 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 689.8K | 313.1K |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $85,513,000.00 | N/A |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $2.45 | $279.20 |
| P/E Ratio | $27.88 | ★ N/A |
| Revenue Growth | ★ 0.46 | N/A |
| 52 Week Low | $8.80 | $8.72 |
| 52 Week High | $16.14 | $27.41 |
| Indicator | CAL | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 42.88 |
| Support Level | $10.69 | $17.02 |
| Resistance Level | $11.88 | $19.05 |
| Average True Range (ATR) | 0.81 | 1.26 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 1.49 | 21.77 |
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - Famous Footwear and Brand Portfolio. The Famous Footwear segment is comprised of its Famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. This segment is comprised of wholesale operations that designs, develops, sources, manufactures, markets and distributes branded, licensed and private-label footwear. Geographically, the company generates the majority of its revenue from Domestic operations.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.